Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

IBD

Phase II results for IBD drugs

Nature Reviews Gastroenterology & Hepatology volume 9, page 62 (2012)Cite this article

Subjects

Current treatment guidelines do not recommend the use of antibiotics in patients with Crohn's disease. However, evidence suggests that an altered immune response to commensal gut bacteria might have a role in the development and persistence of intestinal inflammation in these patients. Thus, antibiotics might have a role in treatment.

Rifaximin is an oral, minimally absorbed antibiotic that has demonstrated efficacy in patients with intestinal bacterial infections, IBS and hepatic encephalopathy. Cosimo Prantera and colleagues performed a multicenter, randomized, double-blind trial of 400, 800 and 1,200 mg rifaximin given twice daily for 12 weeks to patients with moderately active Crohn's disease. 402 patients were included in the trial and the primary end point was remission. The researchers found that 800 mg rifaximin was associated with higher rates of remission than placebo and the 400 mg and 1,200 mg rifaximin doses. These findings now need to be confirmed in pivotal studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPERS

  1. Prantera, C. et al. Rifaximin-extended intestinal release induces remission of patients with moderately active Crohn's disease. Gastroenterology doi:10.1053/j.gastro.2011.11.032

  2. Parikh, A. et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm. Bowel Dis. doi:10.1002/ibd.21896

Download references

Authors
  1. Isobel Franks
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Franks, I. Phase II results for IBD drugs. Nat Rev Gastroenterol Hepatol 9, 62 (2012). https://doi.org/10.1038/nrgastro.2011.265

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrgastro.2011.265

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing